Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls
Infections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent resp...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-02-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1534516 |
| _version_ | 1797677421036568576 |
|---|---|
| author | S. Shahzad Mustafa Deep Shah Jonathan Bress Saad Jamshed |
| author_facet | S. Shahzad Mustafa Deep Shah Jonathan Bress Saad Jamshed |
| author_sort | S. Shahzad Mustafa |
| collection | DOAJ |
| description | Infections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent response, it is recommended in patients with multiple myeloma. This study compares the initial response to PCV13 and durability of the response at 6 months in patients with multiple myeloma versus normal controls. Seven patients with multiple myeloma and 18 control patients were enrolled in the study. Streptococcal pneumonia serotype IgG titers were drawn at baseline, day 30, and day 180 after MM patients and controls received PCV13. Although vaccination with PCV13 produced a similar initial response in patients with multiple myeloma compared to control subjects, the duration of response may have waned in patients with multiple myeloma as compared to control subjects. |
| first_indexed | 2024-03-11T22:44:58Z |
| format | Article |
| id | doaj.art-89cbb448b27b4ab4ae7629b302fd3969 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:44:58Z |
| publishDate | 2019-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-89cbb448b27b4ab4ae7629b302fd39692023-09-22T08:38:24ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-02-0115245245410.1080/21645515.2018.15345161534516Response to PCV13 vaccination in patients with multiple myeloma versus healthy controlsS. Shahzad Mustafa0Deep Shah1Jonathan Bress2Saad Jamshed3Rochester Regional HealthRochester Regional HealthRochester Regional HealthRochester Regional HealthInfections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent response, it is recommended in patients with multiple myeloma. This study compares the initial response to PCV13 and durability of the response at 6 months in patients with multiple myeloma versus normal controls. Seven patients with multiple myeloma and 18 control patients were enrolled in the study. Streptococcal pneumonia serotype IgG titers were drawn at baseline, day 30, and day 180 after MM patients and controls received PCV13. Although vaccination with PCV13 produced a similar initial response in patients with multiple myeloma compared to control subjects, the duration of response may have waned in patients with multiple myeloma as compared to control subjects.http://dx.doi.org/10.1080/21645515.2018.1534516multiple myelomapcv13vaccination |
| spellingShingle | S. Shahzad Mustafa Deep Shah Jonathan Bress Saad Jamshed Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls Human Vaccines & Immunotherapeutics multiple myeloma pcv13 vaccination |
| title | Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls |
| title_full | Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls |
| title_fullStr | Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls |
| title_full_unstemmed | Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls |
| title_short | Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls |
| title_sort | response to pcv13 vaccination in patients with multiple myeloma versus healthy controls |
| topic | multiple myeloma pcv13 vaccination |
| url | http://dx.doi.org/10.1080/21645515.2018.1534516 |
| work_keys_str_mv | AT sshahzadmustafa responsetopcv13vaccinationinpatientswithmultiplemyelomaversushealthycontrols AT deepshah responsetopcv13vaccinationinpatientswithmultiplemyelomaversushealthycontrols AT jonathanbress responsetopcv13vaccinationinpatientswithmultiplemyelomaversushealthycontrols AT saadjamshed responsetopcv13vaccinationinpatientswithmultiplemyelomaversushealthycontrols |